Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06588595

The Switching Antiplatelet-9 (SWAP-9) Study

Led by University of Florida · Updated on 2026-02-25

90

Participants Needed

1

Research Sites

121 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).

CONDITIONS

Official Title

The Switching Antiplatelet-9 (SWAP-9) Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients who have undergone PCI and are on maintenance treatment with dual antiplatelet therapy composed of low-dose aspirin (81 mg daily) with either prasugrel (10 mg daily) or ticagrelor (90 mg twice daily)
  • Patients who had PCI for acute coronary syndrome are eligible after at least 90 days post-PCI
  • Patients who had PCI for chronic coronary syndrome are eligible after at least 30 days post-PCI
  • Age 18 years or older
  • Provide written informed consent
Not Eligible

You will not qualify if you...

  • Prior history of stent thrombosis
  • PCI within the last 30 days
  • Current treatment with any oral anticoagulant medication (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin for venous thrombosis treatment
  • Hemodynamic instability
  • Known hypersensitivity to clopidogrel
  • Known platelet count less than 80 x 10^6/mL
  • Known hemoglobin less than 9 g/dL
  • Pregnant or breastfeeding women (women of childbearing age must use reliable birth control while participating)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Florida

Jacksonville, Florida, United States, 32209

Actively Recruiting

Loading map...

Research Team

L

Luis Ortega, MD, PhD

CONTACT

A

Andrea Burton, MPH, CCRP

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

The Switching Antiplatelet-9 (SWAP-9) Study | DecenTrialz